Does Bristol's tarnished rep put CEO among the year's worst?

Poor Lamberto Andreotti. Just a year ago, the Bristol-Myers Squibb ($BMY) CEO was accepting bouquets for his company's better-than-the-rest reputation in Big Pharma. Now, he's nominated as the year's worst CEO.

What happened? Inhibitex, for one thing. Andreotti's company bought the hepatitis C drugmaker in January for $2.5 billion, on the promise of its lead drug. In August, it dropped the experimental treatment on safety concerns and wrote off $1.8 billion on the Inhibitex deal. It was a particularly dramatic example of how a deal can go bad--and vindication for those who figured Bristol overpaid for Inhibitex in any case.

But that's not all, Bloomberg says. There's Eliquis, the blood thinner Bristol-Myers developed with Pfizer ($PFE). In June, FDA delayed the approval, once again, putting the drug on the back foot against rivals in the warfarin alternative market. Though Eliquis is still pegged as a potential blockbuster, the delay gives Boehringer Ingelheim's Pradaxa and Bayer and Johnson & Johnson's ($JNJ) Xarelto even longer to capture market share.

Motley Fool is a bit more scathing; in nominating Andreotti for worst-CEO honors, the investment site deemed Bristol's famous "string of pearls" strategy a failure. It echoes Bloomberg in noting that Bristol-Myers shares have underperformed their peers this year. The stock dropped 1.8% this year when other pharmas have gained, the Fool says. And despite the stumbles, Andreotti got a 27% pay raise.

Analysts have downgraded the stock, Bloomberg reports. Only 9 of 24 who follow Bristol-Myers recommend buying. Thanks to a previous run-up, it's pricey compared with other drugmakers' shares.

Some say, however, that Bristol-Myers' new tarnish is relative. "Bristol was very successful last year and got a little bit more rich on the valuation basis," Fund Manager Les Funtleyder told Bloomberg. "Then they had a change where the news wasn't terrible but wasn't favorable, like the Inhibitex thing, and the rest of the industry saw more positive news flow."

- read the Bloomberg story
- check out the Fool article

Special Report: Lamberto Andreotti - Bristol-Myers Squibb -- Top 10 Pharma CEO Salaries of 2011

Related Articles:
How does pharma's CEO pay rank?
Sanofi, Bristol revamp Plavix partnership for post-patent world
Bristol-Myers' Q4 shows growth in newer products

Suggested Articles

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.

This week, Goldman Sachs resurrected a burning question: How can pharma companies profit from curing patients with one-time gene and cell therapies?

CMS has determined how it'll pay for Gilead's CAR-T cancer therapy, Yescarta, for outpatient use, but hasn't yet decided on Gilead's…